Table 2 Assessment of the clinical variables of the parkinsonian patients
M−1M+3M+16p Value*
LEDD (mg/day)1135.4 (91.4)622.4 (55.4)741.1 (68.5)<0.001
UPDRS III M “off”/S “off”31.5 (2.0)33.8 (3.0)34.4 (1.7)NS
UPDRS III M “off”/S “on”12.9 (1.5)16.3 (1.4)NS
UPDRS III M “on”/S “off”6.5 (0.8)11.0 (1.3)9.3 (0.9)NS
UPDRS III M “on” S “on”6.8 (0.9)8.9 (0.9)NS
Hoehn and Yahr “off”2.4 (0.1)1.9 (0.1)2.3 (0.1)NS
Hoehn and Yahr “on”1.7 (0.2)1.5 (0.2)1.6 (0.2)NS
LID duration1.5 (0.2)0.3 (0.1)0.1 (0.1)<0.001
LID severity1.3 (0.2)0.1 (0.1)0.1 (0.1)<0.01
“Off” period duration1.6 (0.1)0.6 (0.1)0.9 (0.1)<0.01
UPDRS I1.3 (0.2)1.1 (0.2)1.6 (0.4)NS
UPDRS II “off”17.0 (0.8)10.11 (1.0)12.3 (0.9)<0.001
UPDRS II “on”3.5 (0.7)5.6 (0.8)7.9 (0.6)<0.001
  • p Values were calculated by Friedman analysis for multiple comparisons.

  • LID, levodopa induced dyskinesia; LEDD, levodopa equivalent daily dose; M, medication; S, stimulation; UPDRS, Unified Parkinson Disease Rating Scale.